Clinical impact of a combined therapy of peritoneal dialysis and hemodialysis

Clinical Nephrology

Volumn 74, Issue 3, 2010, Pages 209-216

  Matsuo, N ^a   Yokoyama, K ^a   Maruyama, Y ^a   Ueda, Y ^a   Yoshida, H ^a   Tanno, Y ^a   Yamamoto, R ^a   Terawaki, H ^a   Ikeda, M ^a   Hanaoka, K ^a   Yamamoto, H ^a   Ogura, M ^a   Watanabe, S ^b   Kimura, Y ^a   Hosoya, T ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kobari General Hospital   (Japan)

Author keywords

Combined therapy; Peritoneal equilibration test; Renal anemia

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; HEMOGLOBIN; INTERLEUKIN 6; RECOMBINANT ERYTHROPOIETIN; BIOLOGICAL MARKER;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; BLOOD VOLUME; BODY FLUID; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DIALYSATE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEALTH STATUS; HEMODIALYSIS; HUMAN; HYDRATION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; RETICULOCYTE COUNT; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT PLANNING; UREMIA; BLOOD; CHI SQUARE DISTRIBUTION; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PROCEDURES; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CREATININE; FEMALE; FIBRINOGEN; HEMOGLOBINS; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 77957171970     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp74209     Document Type: Article

References (39)

1. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol. 2000; 11: 116-125.
2. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001; 12: 2158-2162.
3. Rocco MV, Frankenfield DL, Prowant B, Frederick P, Flanigan MJ. Centers for Medicare & Medicaid Services Peritoneal Dialysis Core Indicators Study Group: Risk factors for early mortality in U.S. peritoneal dialysis patients: impact of residual renal function. Perit Dial Int. 2002; 22: 371-379.
4. Chung SH, Heimbürger O, Stenvinkel P, Qureshi AR, Lindholm B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant. 2003; 18: 590-597.
5. McIntyre CW. Bimodal dialysis: an integrated approach to renal replacement therapy. Perit Dial Int. 2004; 24: 547-553.
6. Kawanishi H, Hashimoto Y, Nakamoto H. Combination therapy with peritoneal dialysis and hemodialysis. Perit Dial Int. 2006; 26: 150-154.
7. Agarwal M, Clinard P, Burkart JM. Combined peritoneal dialysis and hemodialysis: our experience compared to others. Perit Dial Int. 2003; 23: 157-161.
8. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, Kin M, Nakamoto M, Ohira S, Shoji T. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004; 44: 729-737.
9. Yamamoto R, Otsuka Y, Nakayama M, Maruyama Y, Katoh N, Ikeda M, Yamamoto H, Yokoyama K, Kawaguchi Y, Matsushima M. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol. 2005; 9: 148-152.
10. Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H, Tranaeus A. Recommendations on themanagement of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int. 2005; 25 (Suppl.): 83-95.
11. Yokoyama K, Yoshida H, Matsuo N, Maruyama Y, Kawamura Y, Yamamoto R, Hanaoka K, Ikeda M, Yamamoto H, Nakayama M, Kawaguchi Y, Hosoya T. Serum beta2 microglobulin (beta2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. Clin Nephrol. 2008; 69: 121-126.
12. Fujimori A, Naito H, Miyazaki T, Azuma M, Hashimoto S, Horikawa S, Tokukoda Y. Elevation of interleukin-6 in the dialysate reflects peritoneal stimuli and deterioration of peritoneal function. Nephron. 1996; 74: 471-472.
13. Nakayama M, Yamamoto H, Ikeda M, Hasegawa T, Kato N, Takahashi H, Otsuka Y, Yokoyama K, Yamamoto R, Kawaguchi Y, Hosoya T. Risk factors and preventive measures for encapsulating peritoneal sclerosis-Jikei experience 2002. Adv Perit Dial. 2002; 18: 144-148.
14. Kawanishi H, Fujimori A, Tsuchida K, Takemoto Y, Tomo T, Minakuchi J, Yamamoto T, Kim M, Numata A, Choh S, Naito H: Peritoneal Effluent Study Group Japan. Markers in peritoneal effluent forwithdrawal from peritoneal dialysis: multicenter prospective study in Japan. Adv Perit Dial. 2005; 21: 134-138.
15. Mujais S, Nolph K, Gokal R, Blake P, Burkart J, Coles G, Kawaguchi Y, Kawanishi H, Korbet S, Krediet R, Lindholm B, Oreopoulos D, Rippe B, Selgas R. Evaluation and management of ultrafiltration problems in peritoneal dialysis. Perit Dial Int. 2000; 20 (Suppl): 5-21.
16. Plum J, Schoenicke G, Kleophas W, Kulas W, Steffens F, Azem A, Grabensee B. Comparison of body fluid distribution between chronic haemodialysis and peritoneal dialysis patients as assessed by biophysical and biochemical methods. Nephrol Dial Transplant. 2001; 16: 2378-2385.
17. Asci G, Ozkahya M, Duman S, Toz H, Erten S, Ok E. Volume control associated with better cardiac function in long term peritoneal dialysis patients. Perit Dial Int. 2006; 26: 85-88.
18. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996; 334: 420-425.
19. Ifudu O, Uribarri J, Rajwani I, Vlacich V, Reydel K, Delosreyes G, Friedman EA. Adequacy of dialysis and differences in hematocrit among dialysis facilities. Am J Kidney Dis. 2000; 36: 1166-1174.
20. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997; 8: 1921-1929.
21. Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, Owen WF Jr. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol. 2002; 13: 1288-1295.
22. Bárány P, Divino Filho JC, Bergström J. High C-reactive protein is a strong predictor of resistance to erythropoietin. Am J Kidney Dis. 1997; 29: 565-568.
23. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant. 2001; 16 (Suppl): 36-40.
24. Tonelli M, Blake PG, Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J. 2001; 47: 82-85.
25. Nakamoto H, Kanno Y, Okada H, Suzuki H. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2004; 20: 111-116.
26. Pajek J, Bucar-Pajek M, Grego K, Gucek A, Bevc S, Ekart R, Vujkovac B, Golob-Kosmina P, Kandus A, Bren AF. Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian study. Ther Apher Dial. 2005; 9: 228-232.
27. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int. 2005; 68: 2323-233.
28. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008; 3: 1077-1083.
29. Igarashi Y, Watanabe E. The investigation of feeling about combined therapy with peritoneal dialysis and hemodialysis. Hukumakutouseki. 2000; 49: 442-444.
30. Hashimoto Y, Matsubara T. Combined peritoneal dialysis and hemodialysis therapy improves quality of life in end stage renal disease patients. Adv Perit Dial. 2000; 16: 108-112.
31. Konings CJ, Kooman JP, Schonck M, Struijk DG, Gladziwa U, Hoorntje SJ, van der Wall Bake AW, van der Sande FM, Leunissen KM. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant. 2003; 18: 797-803.
32. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI. What really happens to people on long-term peritoneal dialysis? Kidney Int. 1998; 54: 2207-2217.
33. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001; 12: 1046-1051.
34. de Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez-Reyes MJ, Romero JR, Jimenez C, Miranda B, Selgas R. Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial. 1993; 9: 56-61.
35. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55: 1899-1911.
36. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658.
37. Chung SH, Heimbürger O, Stenvinkel P, Wang T, Lindholm B. Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int. 2003; 23: 174-183.
38. Kim KJ, Yang WS, Kim SB, Lee SK, Park JS. Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Perit Dial Int. 1997; 17: 157-161.
39. Yokoyama K, Matsuo N, Yoshida H, Sherif AM, Yaginuma T, Yamamoto H, Kawakami M, Hosoya T. Middle molecular uremic substances retention itself might influence the biocompatibility of PD solution. Kidney Int. 2008; 74: 822.